IMR Press / EJGO / Volume 21 / Issue 5 / pii/2000226

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Immunohistochemical analysis of nm23-Hl expression in human cervical lesions

Show Less
1 Departments of Pathology and Gynecology, University of Patras, School of Medicine, Patras, Greece
Eur. J. Gynaecol. Oncol. 2000, 21(5), 510–512;
Published: 10 October 2000

Reduced expression of the metastasis suppressor gene nm23-Hl has been previously correlated with high tumor metastatic poten­tial and fatal clinical outcome in several types of human carcinomas. The aim of the study was to identify the expression of nm23-Hl in a variety of premalignant and malignant cervical lesions. The study comprised 106 cervical biopsies obtained from 106 women ranging in age from 23 to 68 (median 42) years. Histologic slides stained with H&E were evaluated blindly by two pathologists and a consensus diagnosis was established for each case. In addition, immunohistochemical stain was employed and a monoclonal antibody against nm23-Hl (YLEM Rome, Italy) was used. Twenty-five of the cervical biopsies showed changes of mild dysplasia (CINI), whereas 28 demonstrated features of moderate dysplasia (CIN II) and 28 severe dysplasia (CIN III). In 25 cases infiltrating squamous cell carcinoma was identified. Expression of nm23-Hl was evident in 9/25 (36%) CINI, 13/28 (46%) CIN II, 22/28 (78.5%) CIN III and 17 /25 (68%) infiltrating carcinoma bio­psies. Statistically significant differences were observed between CIN II and CIN III (p = 0.003), and CIN II and infiltrating carci­noma (p = 0.002) groups. Expression of the nm23-Hl gene in premalignant and malignant cervical lesions indicates that this gene may play a substantial role in carcinogenesis and tumor progression.

Back to top